SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX) announced today that it intends to report the Company's
first quarter 2007 financial results via press release after the financial
markets close on Monday, May 7, 2007. Following the announcement, Evan M.
Levine, Chief Executive Officer and Gregory P. Hanson, Senior Vice
President and Chief Financial Officer are scheduled to host a conference
call and webcast discussion of the results and provide a general corporate
update. Other members of ADVENTRX's executive management team will also be
available to take investor questions. Access to the event can be obtained
as follows:
Live access on Monday, May 7, 2007, 1:30 p.m. Pacific Time / 4:30 p.m.
Eastern Time:
- Telephone (877) 502-9274 (domestic) or (913) 981-5584 (international)
- The webcast will be available live by accessing ADVENTRX's website at
http://www.adventrx.com under "Investors"
Replay access:
- Telephone replay will be available through June 7, 2007 by dialing
888-203-1112 and entering the passcode 4320902
- Replays of the webcast will be available by accessing ADVENTRX's website
at http://www.adventrx.com under "Investors" for 30 days
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems, such as drug metabolism and
bioavailability, excessive toxicity and treatment resistance. The Company's
lead product candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b
clinical trials for the treatment of metastatic colorectal cancer, as well
as in a Phase 2 clinical trial for the treatment of advanced breast cancer.
More information can be found on ADVENTRX's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These potential risks and uncertainties
include, but are not limited to: the risk that ADVENTRX will be unable to
raise sufficient capital to fund the projects necessary to meet its
anticipated or stated goals and milestones; the potential to attract a
strategic partner and the terms of any related transaction; the ability to
timely enroll subjects in ADVENTRX's current and anticipated clinical
trials; the potential for CoFactor and ADVENTRX's other product candidates
to receive regulatory approval for one or more indications on a timely
basis or at all, and the uncertain process of seeking regulatory approval;
other difficulties or delays in developing, testing, manufacturing and
marketing of and obtaining regulatory approval for CoFactor or ADVENTRX's
other product candidates; the potential for regulatory authorities to
require additional preclinical work or other clinical requirements to
support regulatory filings; the scope and validity of patent protection for
CoFactor and ADVENTRX's other product candidates; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are available at
http://www.sec.gov.
ADVENTRX assumes no obligation to revise or update any forward-looking
statement, including as set forth in this press release, to reflect events
or circumstances arising after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/gh/cnoc/comp/920134.html /
CONTACT:
Investors: Ioana C. Hone for ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866; Media: Edie DeVine of
WeissComm Partners, +1-415-946-1081
|
